Cover Image
Market Research Report

Critical Outcome Technologies Inc. - Product Pipeline Review - 2016

Published by Global Markets Direct Product code 204909
Published Content info 43 Pages
Delivery time: 1-2 business days
Price
Back to Top
Critical Outcome Technologies Inc. - Product Pipeline Review - 2016
Published: October 19, 2016 Content info: 43 Pages
Description

Summary:

Global Markets Direct's, 'Critical Outcome Technologies Inc. - Product Pipeline Review - 2016', provides an overview of the Critical Outcome Technologies Inc.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Critical Outcome Technologies Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the pipeline therapeutic landscape of Critical Outcome Technologies Inc.
  • The report provides overview of Critical Outcome Technologies Inc. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Critical Outcome Technologies Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Critical Outcome Technologies Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy:

  • Evaluate Critical Outcome Technologies Inc.'s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Critical Outcome Technologies Inc.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Critical Outcome Technologies Inc.'s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Product Code: GMDHC08159CDB

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Critical Outcome Technologies Inc. Snapshot
    • Critical Outcome Technologies Inc. Overview
    • Key Facts
  • Critical Outcome Technologies Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Critical Outcome Technologies Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Critical Outcome Technologies Inc. - Pipeline Products Glance
    • Critical Outcome Technologies Inc. - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • Critical Outcome Technologies Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Critical Outcome Technologies Inc. - Drug Profiles
    • COTI-2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • COTI-219 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • COTI-4 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • COTI-58 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for MRSA Infection - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Acute Myelocytic Leukemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Small Cell Lung Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize VEGF-R and PDGF-R for Multiple Sclerosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Angiogenesis for Undisclosed Indication - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Beta Secretase and Gamma Secretase for Alzheimer's Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit CDKs for Colorectal Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit HIV-1 Integrase for HIV-1 Infection - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Microtubulin for Colorectal Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Thymidylate Synthase and THFR for Colorectal Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Critical Outcome Technologies Inc. - Pipeline Analysis
    • Critical Outcome Technologies Inc. - Pipeline Products by Target
    • Critical Outcome Technologies Inc. - Pipeline Products by Route of Administration
    • Critical Outcome Technologies Inc. - Pipeline Products by Molecule Type
    • Critical Outcome Technologies Inc. - Pipeline Products by Mechanism of Action
  • Critical Outcome Technologies Inc. - Dormant Projects
  • Critical Outcome Technologies Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Critical Outcome Technologies Inc., Key Facts
  • Critical Outcome Technologies Inc. - Pipeline by Indication, 2016
  • Critical Outcome Technologies Inc. - Pipeline by Stage of Development, 2016
  • Critical Outcome Technologies Inc. - Monotherapy Products in Pipeline, 2016
  • Critical Outcome Technologies Inc. - Phase I, 2016
  • Critical Outcome Technologies Inc. - Preclinical, 2016
  • Critical Outcome Technologies Inc. - Discovery, 2016
  • Critical Outcome Technologies Inc. - Pipeline by Target, 2016
  • Critical Outcome Technologies Inc. - Pipeline by Route of Administration, 2016
  • Critical Outcome Technologies Inc. - Pipeline by Molecule Type, 2016
  • Critical Outcome Technologies Inc. - Pipeline Products by Mechanism of Action, 2016
  • Critical Outcome Technologies Inc. - Dormant Developmental Projects,2016

List of Figures

  • Critical Outcome Technologies Inc. - Pipeline by Top 10 Indication, 2016
  • Critical Outcome Technologies Inc. - Pipeline by Stage of Development, 2016
  • Critical Outcome Technologies Inc. - Monotherapy Products in Pipeline, 2016
  • Critical Outcome Technologies Inc. - Pipeline by Top 10 Target, 2016
  • Critical Outcome Technologies Inc. - Pipeline by Route of Administration, 2016
  • Critical Outcome Technologies Inc. - Pipeline by Molecule Type, 2016
  • Critical Outcome Technologies Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top